AI assistant
Vaishali Pharma Limited Interim / Quarterly Report 2022
62707_rns_2021-07-24_5b7ab836-8af7-4699-969e-c86b752239ce.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
Vaishali Pharma Ltd.
CORPORATE & REGISTERED OFFICE: 706-709. 7th Floor. Aravali Business Centre. R. C. Patel Road, Off. Sodawala Lane, Borivali (West), Mumbai-400 092. Tel.: +91-22-4217 1819 E-mail: [email protected] CIN - L52310MH2008PLC181632
24th July, 2021
To. National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex. Bandra (East), Mumbai - 400 051
Stock Code: VAISHALI
SUB: OUTCOME UNDER OF THE MEETING OF THE BOARD OF DIRECTORS OF THE COMPANY HELD TODAY ON 24TH JULY, 2021.
Dear Sir/Madam,
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its meeting held today, has considered and approved the Un-audited Standalone Financial Results along with Limited Review Report for the Quarter Ended 30th June 2021, copy of the same is enclosed herewith.
Further, the Board Meeting commenced at 03:00 pm and concluded at 03:30 pm.
Kindly take the above on records.
Thanking you.
Yours faithfully, For Vaishali Pharma Limited
Akshay Theorkhoundi
Akshay Jharkhandi Company Secretary & Compliance Officer
Enclosed:-
- Un-Audited Standalone Financial Results for the Quarter Ended 30th June, 2021;
- Limited Review Report issued by Chartered Accountant, M/s. Raman S. Shah & Associates, Chartered Accountants, for the Quarter Ended 30th June, 2021.
Vaishali Pharma Ltd.
CORPORATE & REGISTERED OFFICE: 706-709, 7th Floor, Aravali Business Centre, R. C. Patel Road, Off. Sodawala Lane, Borivali (West), Mumbai-400 092. Tel.: +91-22-4217 1819 E-mail : [email protected] CIN - L52310MH2008PLC181632
(Rs. In Lakhs)
| Sr. | Particulars | Quarter Ended | Ouarter Ended | Quarter Ended | Year Ended |
|---|---|---|---|---|---|
| No. | $30 - Jun - 21$ | $31-Mar-21$ | $30 - Jun-20$ | 31-Mar-21 | |
| (Unaudited) | (Unaudited) | (Unaudited) | (Audited) | ||
| T | Revenue from operationsSales/income from operationsa)b) Other operating income | 813.8513.14 | 1,772.77115.39 | 345.6311.00 | 5,230,77146.62 |
| Total Revenue from operations | 826.99 | 1,888.16 | 356.63 | 5,377.39 | |
| $\overline{c}$ | Other income | 56.67 | 57.33 | 54.17 | 180.91 |
| 3 | Total Income (1+2) | 883.66 | 1,945.49 | 410.80 | 5,558.30 |
| $\frac{4}{3}$ | Expenditurea) Purchase of Stock-in-tradeb) Changes in Inventories of Finished Goods, Work-in-progress and Stock-in-trade | 629.33(1.10) | 1.736.5735.89 | 277.8925.87 | 4,585.9629.19 |
| Employee benefit expensesc)Finance costdDepreciation and amortisation expensesc) | 41.9365.2010.1929.86 | 48.96106.7411.30202.70 | 45.6144.4110.266.43 | 184.77261.0742.69314.17 | |
| Other expensesÐTotal Expenses (a to f) | 775.41 | 2,142.16 | 410.47 | 5,417.85 | |
| 5 | Profit before Exceptional Items and Tax | 108.25 | (196.67) | 0.33 | 140.45 |
| 6 | Exceptional items debit / (credit) | ä, | |||
| $-7$ | Profit before Tax | 108.25 | (196.67) | 0.33 | 140.45 |
| 8 | Tax ExpensesCurrent Tax (Net) Debit / (Credit)Deferred Tax (Net) Debit / (Credit)Tax for earlier year | 27.06٠ | (49.77)(2.06) | 0.10٠ | 37.88(2.06) |
| Total Tax Expenses | 27.06 | (51.83) | 0.10 | 35.82 | |
| 9 | Net Profit for the period | 81.19 | (144.84) | 0.23 | 104.63 |
| 10 | Other Comprehensive Incomea) Items that will not be reclassified to profit and loss(Net of Tax)- Remeasurements of the defined benefit plans :(Losses)/ Gains | (0.91) | ö | (0.91) | |
| 11 | Total comprehensive income for the period | 81.19 | (145.75) | 0.23 | 103.72 |
| 1213 | Paid up Equity Share Capital (Face Value of Rs. 10/-)Earning Per Share (For continuing operations based onWeighted Average) -In INR (Not Annualised) | 1,054.62 | 1.054.62 | 1,054.62 | 1,054.62 |
| BasicDiluted | 0.770.77 | (1.37)(1.37) | 0.010.01 | 0.990.99 |
Statement of Unaudited Standalone Financial Results for the Quarter Ended June 30, 2021
For and on behalf of the Board
FOR VAISHALI PHARMA LTD.
pe
DIRECTOR
a
Place : Mumbai Date: 24/07/2021
An ISO 9001:2015 Certified Company Website : www.vaishalipharma.com
CHARTERED
ACCOUNTANTS FIRM REGN
No. 119891W
BOISAR
Vaishali Pharma Ltd.
CORPORATE & REGISTERED OFFICE: 706-709, 7th Floor, Aravall Business Centre, R. C. Patel Road, Off. Sodawala Lane, Borivali (West), Mumbai-400 092. Tel.: +91-22-4217 1819 E-mail : [email protected] CIN - L52310MH2008PLC181632
-
- The above financial results for the quarter ended 30th June, 2021 were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 24th July, 2021.
- The above Unaudited Financial results is subject to Limited Review Report as furnished by the Statutory Auditors and $2.$ approved by the Board of Directors of the Company as received under regulation 33 of SEBI (LODR) Regulation 2015.
-
- Figures of previous reporting periods have been regrouped / reclassified wherever necessary to correspond with the figures of the current reporting period.
-
- The Company has one segment of activity viz., Sale of pharmaceutical products.
Place: Mumbai Date: 24th July 2021
By the order of the Board For Vaishali Pharma Limited
Director
An ISO 9001:2015 Certified Company Website: www.vaishalipharma.com
RAMAN S. SHAH & ASSOCIATES CHARTERED ACCOUNTANTS
CA Raman S. Shah, B.Com, F.C.A. CA Santosh A. Sankhe, B.Com, F.C.A. CA Bharat C. Bhandari, B.Com, F.C.A.
LIMITED REVIEW REPORT
To. The Board of Directors VAISHALI PHARMA LTD.
- We have reviewed the accompanying statement of unaudited standalone financial results of $1.$ VAISHALI PHARMA LTD for the period ended 30th June, 2021 & year to date results for the period 1st April, 2021 to 30th June, 2021 attached herewith.
- The preparation of the statement is the responsibility of the Company's Management and has $2.$ been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
- We conducted our review in accordance with the Standard on Review Engagement (SRE) $3.$ _2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (IND-AS) and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circulars issued from time to time including the manner in which it is to be disclosed, or that it contains any material misstatement.
COUNTANT EIDM REGI
For Raman S. Shah & Associates Chartered Accountants
CA Santosh A. Sankhe Partner Membership No:- 100976 FRN No: - 119891W Place: Mumbai Date: 24th July, 2021 UDIN 21100976AAAAEQ2604
Head Office :- Sam Plaza,'A' Wing,IInd Floor,H.K.Irani Road,Dahanu Road (W) 401602 Branch Office:-1)A-104,Ist Floor,Inder Darshan Building,Jamli Gali,Borivali(W),Mumbai(W),400092 2)118-121, Ist Floor, "Harmony Plaza", Tarapur Road, Boisar, 401501
$4.$